The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer.

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer.

Numerous clinical trials are always active (i.e., open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. This section of the website contains a searchable list of all active trials.

Group-wide meetings of the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) occur twice a year and are open to researchers and staff affiliated with member institutions, patient advocates who are members of ECOG-ACRIN's various scientific committees, industry representatives, and invited individuals from external (non-member) organizations.

The ECOG Performance Status Scale and the Karnofsky Performance Status Scale are two widely used methods to assess the functional status of a patient. Both scales are in the public domain to classify a patient according to their functional impairment, compare the effectiveness of therapies, and assess the prognosis of a patient.

The ECOG-ACRIN Cancer Research Group consists of a headquarters location and several fully staffed centers and offices, all of which oversee the governance, operations, and scientific programs of the Group. These centers and offices are shown below.

ECOG Performance Status Scale and a variety of other resources gather together in a central location to assist researchers conducting cancer clinical trials

2025年1月15日 · The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced today by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN).

The Principal Investigator (PI) Committee of the ECOG-ACRIN Cancer Research Group is one of two committees that govern the Group under the leadership of the Group Co-Chairs (the other is the Executive Committee).

2024年12月10日 · The finding is from the phase 3 study EA4151, Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Patient enrollment in the trial was stopped early after a planned interim analysis failed ...